Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study

被引:85
作者
Melia, J [1 ]
Moss, S [1 ]
Johns, L [1 ]
机构
[1] Inst Canc Res, Canc Screening Evaluat Unit, Sutton SM2 5NG, Surrey, England
关键词
prostate specific antigen; PSA; mass screening; prostatic neoplasms; primary health care; England; Wales;
D O I
10.1111/j.1464-4096.2004.04832.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To assess the rate of prostate-specific antigen (PSA) testing for prostate cancer in general practice in asymptomatic and symptomatic patients. Subjects and Methods The cross-sectional study took place in England and Wales, was population-based and covered 469 159 men aged 45-84 years. Pathology data on PSA tests requested between 19 November 1999 and 31 May 2002 by general practitioners (GPs) were provided by 28 pathology laboratories. The practices recorded reasons for the tests between 1 December 2001 and 31 May 2002. In all, 391 practices in which all GP partners participated were included in the analyses. Results The overall annual rate of testing in men with no previous diagnosis of prostate cancer was estimated to be 6%, of which the annual rates of asymptomatic, symptomatic and re-testing were 2.0%, 2.8% and 1.2%, respectively, after adjusting for missing values. The rate decreased with increasing social deprivation, and with increasing proportions of black and Asian populations. The overall rate of PSA testing increased significantly from 1999 to 2002. Conclusions If the recommendations of the National Health Service Prostate Cancer Risk Management Programme were applied, 14% of asymptomatic tests and 23% of symptomatic tests would have led to a referral. As the rate of PSA testing is increasing and there are uncertainties about the benefit of screening, the workload and costs in general practice and hospitals should be monitored.
引用
收藏
页码:51 / 56
页数:6
相关论文
共 15 条
[1]  
[Anonymous], 1988, HLTH DEPRIVATION INE
[2]  
Chamberlain J, 1997, BRIT J UROL, V79, P1
[3]   Large-scale randomized prostate cancer screening trials:: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial [J].
de Koning, HJ ;
Auvinen, A ;
Sanchez, AB ;
da Silva, FC ;
Ciatto, S ;
Denis, L ;
Gohagan, JK ;
Hakama, M ;
Hugosson, J ;
Kranse, R ;
Nelen, V ;
Prorok, PC ;
Schröder, FH .
INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (02) :237-244
[4]   Screening for prostate cancer in the UK - Seems to be creeping in by the back door [J].
Donovan, JL ;
Frankel, SJ ;
Neal, DE ;
Hamdy, FC .
BMJ-BRITISH MEDICAL JOURNAL, 2001, 323 (7316) :763-764
[5]   Prostate-specific antigen testing in black and white men: An analysis of Medicare claims from 1991-1998 [J].
Etzioni, R ;
Berry, KM ;
Legler, JM ;
Shaw, P .
UROLOGY, 2002, 59 (02) :251-255
[6]   Evidence of prostate cancer screening in a UK region [J].
Kirby, R .
BJU INTERNATIONAL, 2004, 93 (06) :734-734
[7]   CANCER MORTALITY IN AFRICAN AND CARIBBEAN MIGRANTS TO ENGLAND AND WALES [J].
GRULICH, AE ;
SWERDLOW, AJ ;
HEAD, J ;
MARMOT, MG .
BRITISH JOURNAL OF CANCER, 1992, 66 (05) :905-911
[8]  
LUYAO G, 2002, BMJ-BRIT MED J, V325, P1
[9]  
MEDIA J, 2001, BRIT J CANCER, V85, P656
[10]  
Nijs H G, 1997, J Med Screen, V4, P102